All In Biotech

Drug Trial Radar · NCT06423898

Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.

Efficacy and Safety of Ampicillin and Ceftriaxone Continuous Infusion Versus Standard Therapy for the Treatment of Enterococcus Faecalis Infective Endocarditis (DOβLEI Study)

Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 284 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

284

Planned (sponsor's estimate)

Start

Oct 9, 2024

Primary completion

Jul 31, 2027

Study completion Dec 31, 2028

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Spanish Clinical Research Network - SCReN
First posted
May 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase IV, open-label, randomized and multicenter clinical trial to prove that patients with Enterococcus faecalis infective endocarditis treated with an antibiotic treatment as a continuous infusion is non-inferior to the standard treatment, usually administered in hospitalized patients.

Conditions

  • Endocarditis, Infective

Interventions

  • Ampicillin plus ceftriaxone in continuous infusionDrug

    Continuous intravenous antibiotic infusion during 42 days for Infective Endocarditis

  • Ampicillin plus ceftriaxone in intermittent infusion of 14 days, after which the treatment may be changedDrug

    Ampicillin plus ceftriaxone as an intermittent infusion for a minimum of 14 days. After, if the patient is discharged from the hospital, the following treatments, until the 42-day treatment period is completed: 1. Intravenous treatment according to the following regimens: Ampicillin plus ceftriaxone as an intermittent infusion, teicoplanin, daptomycin, dalbavancin or linezolid. 2. Oral treatment according to the following regimens: amoxicillin plus moxifloxacin, amoxicillin plus linezolid, amoxicillin plus rifampin, linezolid plus moxifloxacin or linezolid plus rifampin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical failureTime frame: One year after the end of the treatment

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario de Álava

    Alava, Spain · Recruiting

  • Hospital Universitario de Cruces

    Barakaldo, Spain · Active not recruiting

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain · Not yet recruiting

  • Hospital Clínico de Barcelona

    Barcelona, Spain · Not yet recruiting

  • Hospital Universitario de Donostia

    Donostia / San Sebastian, Spain · Active not recruiting

  • Hospital Universitario Virgen de las Nieves

    Granada, Spain · Active not recruiting

  • Hospital San Pedro

    Logroño, Spain · Active not recruiting

  • Hospital Universitario Gregorio Marañón

    Madrid, Spain · Active not recruiting

  • Hospital Clínico San Carlos

    Madrid, Spain · Not yet recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Not yet recruiting

  • Hospital Universitario Puerta del Hierro

    Madrid, Spain · Active not recruiting

  • Hospital Universitario Regional de Málaga

    Málaga, Spain · Active not recruiting

  • Hospital Universitario Virgen de la Victoria

    Málaga, Spain · Active not recruiting

  • Hospital Universitario de Canarias

    San Cristóbal de La Laguna, Spain · Recruiting

  • Hospital Universitario Marqués de Valdecilla

    Santander, Spain · Recruiting

  • Hospital Universitario Virgen Macarena

    Seville, Spain · Active not recruiting

  • Hospital Universitario Virgen del Rocío

    Seville, Spain · Recruiting

  • Hospital Universitari MútuaTerrassa

    Terrassa, Spain · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.